Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Rating of “Hold” from Analysts

Novavax, Inc. (NASDAQ:NVAX) has been given a consensus recommendation of “Hold” by the five research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $19.00.

A number of research firms have recently issued reports on NVAX. HC Wainwright restated a “buy” rating and set a $19.00 target price on shares of Novavax in a research note on Monday, May 13th. Bank of America raised their price objective on shares of Novavax from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday, June 14th. B. Riley boosted their price objective on Novavax from $11.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, May 23rd. JPMorgan Chase & Co. upgraded Novavax from an “underweight” rating to a “neutral” rating in a research note on Friday, May 10th. Finally, TD Cowen boosted their price target on Novavax from $5.00 to $10.00 and gave the company a “hold” rating in a research note on Monday, May 13th.

Insiders Place Their Bets

In other Novavax news, Director James F. Young sold 7,500 shares of the firm’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $13.72, for a total transaction of $102,900.00. Following the transaction, the director now owns 69,260 shares in the company, valued at approximately $950,247.20. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Novavax news, Director James F. Young sold 7,500 shares of the stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $13.72, for a total transaction of $102,900.00. Following the sale, the director now directly owns 69,260 shares in the company, valued at $950,247.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Filip Dubovsky sold 47,312 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $13.90, for a total transaction of $657,636.80. Following the completion of the transaction, the insider now owns 38,953 shares of the company’s stock, valued at $541,446.70. The disclosure for this sale can be found here. Insiders have sold a total of 62,312 shares of company stock worth $866,212 in the last quarter. Corporate insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Novavax

A number of large investors have recently modified their holdings of the business. Swedbank AB bought a new position in shares of Novavax in the first quarter worth about $26,000. Herr Investment Group LLC bought a new position in shares of Novavax during the first quarter worth about $48,000. Alpine Global Management LLC bought a new position in shares of Novavax during the first quarter worth about $49,000. Ameritas Investment Partners Inc. lifted its stake in shares of Novavax by 31.6% in the first quarter. Ameritas Investment Partners Inc. now owns 11,298 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 2,711 shares during the period. Finally, Edgestream Partners L.P. increased its position in shares of Novavax by 23.7% during the first quarter. Edgestream Partners L.P. now owns 12,753 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 2,447 shares during the period. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Stock Up 0.6 %

NASDAQ:NVAX opened at $12.73 on Tuesday. Novavax has a 12-month low of $3.53 and a 12-month high of $23.86. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of -4.02 and a beta of 1.99. The stock’s 50 day moving average price is $12.15 and its two-hundred day moving average price is $7.27.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.01). The company had revenue of $93.90 million during the quarter, compared to analyst estimates of $71.32 million. During the same quarter in the previous year, the business posted ($3.41) EPS. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. Equities research analysts expect that Novavax will post 0.49 EPS for the current year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.